WHO Pharmaceuticals Newsletter 2002, No. 03
(2002; 22 pages) View the PDF document
Table of Contents
Close this folderREGULATORY MATTERS
View the documentARISTOLOCHIC ACID - Warnings on more products containing Aristolochic acid
View the documentARTHRIN, OSPORO, POENA AND OTHERS - Presence of undeclared prescription drugs poses health threat
View the documentASPIRIN - Restrictions on use in children extended to teenagers
View the documentBACLOFEN - Life threatening sequelae and/or death with abrupt withdrawal of intrathecal injections
View the documentBEJAI BOWYANTAN - Risk of toxicity in children due to presence of Borneol
View the documentCELECOXIB - CLASS findings added to product label
View the documentEPOETIN-ALFA - Important safety update
View the documentGLITAZONES - strengthens labelling for cardiovascular risks
View the documentHORMONE REPLACEMENT THERAPY (HRT) - Product information updated
View the documentIRINOTECAN - Labelling updated
View the documentKAVA-KAVA - More withdrawals due to hepatotoxic risks
View the documentMELOXICAM - Additional information in package insert
View the documentMISOPROSTOL - Major labelling changes
View the documentNIMESULIDE - Temporary suspension pending further evaluation
View the documentOLANZAPINE - Risk of hyperglycaemia
View the documentPOOLED PLASMA (HUMAN) SOLVENT DETERGENT TREATED - Boxed warning to indicate new contraindication
View the documentPROPOFOL - Contraindication section modified
View the documentROFECOXIB - Reports of gastrointestinal/cardio vascular toxicity; labelling updated
View the documentSIROLIMUS - Correction to drug safety information
View the documentSLIM 10 - Withdrawn due to presence of adulterants
View the documentTAMOXIFEN - Boxed warning added to product label
View the documentTETRABAMATE - Withdrawal due to reports of hepatotoxicity
View the documentVALPROATE - Labelling strengthened
View the documentZONISAMIDE - Prescribing information updated
Open this folder and view contentsSAFETY OF MEDICINES
Open this folder and view contentsDRUGS OF CURRENT INTEREST
Open this folder and view contentsFEATURE
View the documentEVENTS & ANNOUNCEMENTS
 

BEJAI BOWYANTAN - Risk of toxicity in children due to presence of Borneol

Canada. Health Canada is warning Canadians not to use Bejai Bowyantan in young children and infants since the product contains borneolum syntheticum, a substance known to be extremely toxic, particularly in children. Bejai Bowyantan is a Chinese medicine used to treat babies with flu, fever, stomach aches, diarrhoea, night crying and inability to sleep. Although no adverse reactions to this product have been reported so far, Health Canada is issuing this advise as a precautionary measure and is in the process of identifying all importers of the product to facilitate its rapid removal from the market. A customs alert will prevent the further importation of the product into Canada.

Reference:

Health Canada Warnings/ Advisories, 14 Jun 2002.

Available from URL: http://www.hc-sc.gc.ca

to previous section to next section
 

Last updated: May 3, 2013